Creagan E T, Long H J, Ahmann D L, Green S J
Am J Clin Oncol. 1984 Oct;7(5):543-4. doi: 10.1097/00000421-198410000-00030.
The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma. The intravenous dose was 250 mg/m2/days 1-3 repeated at 3-week intervals. There were two objective regressions (5%) in conjunction with generally transient and tolerable hematologic and gastrointestinal toxicity. L-alanosine as used in our study has limited activity against malignant melanoma.
